LAUSR

1. Bridges JP, Vladar EK, Huang H, Mason RJ. Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. Thorax 2022;77:203–209. 2. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120–128. 3. Leisman DE, Mehta A, Thompson BT, Charland NC, Gonye ALK, Gushterova I, et al. Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19. Am J Respir Crit Care Med 2022;205: 507–519. 4. Joffre J, Rodriguez L, Matthay ZA, Lloyd E, Fields AT, Bainton RJ, et al., COVID-19 Multi-Phenotyping for Effective Therapies (COMET) Consortium and COVID-19 Associated Coagulopathy, Inflammation, and Thrombosis (Co-ACIT) Study Group. COVID-19–associated lung microvascular endotheliopathy: a “from the bench” perspective. Am J Respir Crit Care Med 2022:206;961–972. 5. Monteil V, Kwon H, Prado P, Hagelkr€ uys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020;181: 905–913.e7. 6. Yu X, Lin Q, Qin X, Ruan Z, Zhou J, Lin Z, et al. ACE2 antagonizes VEGFa to reduce vascular permeability during acute lung injury. Cell Physiol Biochem 2016;38:1055–1062. 7. Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010;87:262–271. 8. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26:1636–1643. 9. Kang S, Kishimoto T. Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Exp Mol Med 2021; 53:1116–1123. 10. Filbin MR, Mehta A, Schneider AM, Kays KR, Guess JR, Gentili M, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survivalassociated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med 2021; 2:100287. 11. Gustafson D, Ngai M, Wu R, Hou H, Schoffel AC, Erice C, et al. Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies. EBioMedicine 2022;78:103982. 12. Schimmel L, Chew KY, Stocks CJ, Yordanov TE, Essebier P, Kulasinghe A, et al. Endothelial cells are not productively infected by SARS-CoV-2. Clin Transl Immunology 2021;10:e1350. 13. Ahmetaj-Shala B, Peacock TP, Baillon L, Swann OC, Gashaw H, Barclay WS, et al. Resistance of endothelial cells to SARS-CoV-2 infection in vitro [preprint]. bioRxiv [accessed 2022 July 1] Available from: https://www.biorxiv.org/content/10.1101/2020.11.08. 372581v1. 14. Li Y, Schneider AM, Mehta A, Sade-Feldman M, Kays KR, Gentili M, et al. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. J Clin Invest 2021;131: 148635. 15. Verhoeven F, Prati C, Maguin-Gat e K, Wendling D, Demougeot C. Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis. Arthritis Res Ther 2016;18:258.